Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Frequently asked questions
What sector does Lunit Inc. (328130) operate in?
Lunit Inc. belongs to the Healthcare sector and operates in the Health Information Services industry.
What is Lunit Inc. (328130) current stock price?
As of the latest data, Lunit Inc. stock price is ₩14,720, with a previous close of ₩14,690. Lunit Inc. gained ₩30 in the last trading session, representing a 0.2% increase.
What is Lunit Inc. (328130) current market capitalization?
Lunit Inc. market cap is approximately 1.10 trillion.
Does Lunit Inc. (328130) pay dividends?
No. Lunit Inc. does not pay a dividend.
What is Lunit Inc. (328130) beta (volatility) score?
Lunit Inc. has a beta of 1.225, suggesting it is more volatile than the market.